Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

572 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis.
Caocci G, Mulas O, Annunziata M, Luciano L, Bonifacio M, Orlandi EM, Pregno P, Galimberti S, Russo Rossi A, Abruzzese E, Iurlo A, Martino B, Sgherza N, Binotto G, Castagnetti F, Gozzini A, Fozza C, Bocchia M, Sicuranza A, Stagno F, Efficace F, Usala E, De Gregorio F, Scaffidi L, Elena C, Pirillo F, Baratè C, Trawinska MM, Cattaneo D, Labate C, Gugliotta G, Molica M, Specchia G, La Nasa G, Foà R, Breccia M. Caocci G, et al. Among authors: breccia m. Am J Hematol. 2018 Jul;93(7):E159-E161. doi: 10.1002/ajh.25102. Epub 2018 Apr 28. Am J Hematol. 2018. PMID: 29633312 Free article. No abstract available.
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.
Palandri F, Iacobucci I, Martinelli G, Amabile M, Poerio A, Testoni N, Soverini S, Castagnetti F, De Vivo A, Breccia M, Specchia G, Abruzzese E, Martino B, Cilloni D, Saglio G, Pane F, Liberati AM, Rosti G, Baccarani M; GIMEMA Working Party on CML. Palandri F, et al. Among authors: breccia m. J Clin Oncol. 2008 Jan 1;26(1):106-11. doi: 10.1200/JCO.2007.13.2373. J Clin Oncol. 2008. PMID: 18165644
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome.
Palandri F, Iacobucci I, Castagnetti F, Testoni N, Poerio A, Amabile M, Breccia M, Intermesoli T, Iuliano F, Rege-Cambrin G, Tiribelli M, Miglino M, Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M; GIMEMA Working Party on CML. Palandri F, et al. Among authors: breccia m. Haematologica. 2008 May;93(5):770-4. doi: 10.3324/haematol.12265. Epub 2008 Mar 26. Haematologica. 2008. PMID: 18367490 Free article. Clinical Trial.
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, Breccia M, Alimena G, Pungolino E, Rege-Cambrin G, Varaldo R, Miglino M, Specchia G, Zuffa E, Ferrara F, Bocchia M, Saglio G, Pane F, Alberti D, Martinelli G, Baccarani M, Rosti G; GIMEMA Working Party on Chronic Myeloid Leukemia. Palandri F, et al. Among authors: breccia m. Haematologica. 2008 Dec;93(12):1792-6. doi: 10.3324/haematol.13068. Epub 2008 Oct 6. Haematologica. 2008. PMID: 18838477 Free article. Clinical Trial.
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results.
Palandri F, Testoni N, Luatti S, Marzocchi G, Baldazzi C, Stacchini M, Castagnetti F, Breccia M, Specchia G, Pane F, Saglio G, Martinelli G, Baccarani M, Rosti G. Palandri F, et al. Among authors: breccia m. Leuk Lymphoma. 2009 Jan;50(1):114-8. doi: 10.1080/10428190802492415. Leuk Lymphoma. 2009. PMID: 19125382 No abstract available.
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up.
Palandri F, Castagnetti F, Alimena G, Testoni N, Breccia M, Luatti S, Rege-Cambrin G, Stagno F, Specchia G, Martino B, Levato L, Merante S, Liberati AM, Pane F, Saglio G, Alberti D, Martinelli G, Baccarani M, Rosti G. Palandri F, et al. Among authors: breccia m. Haematologica. 2009 Feb;94(2):205-12. doi: 10.3324/haematol.13529. Epub 2009 Jan 14. Haematologica. 2009. PMID: 19144656 Free PMC article. Clinical Trial.
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response.
Palandri F, Iacobucci I, Soverini S, Castagnetti F, Poerio A, Testoni N, Alimena G, Breccia M, Rege-Cambrin G, Tiribelli M, Varaldo R, Abruzzese E, Martino B, Luciano L, Pane F, Saglio G, Martinelli G, Baccarani M, Rosti G. Palandri F, et al. Among authors: breccia m. Clin Cancer Res. 2009 Feb 1;15(3):1059-63. doi: 10.1158/1078-0432.CCR-08-1195. Clin Cancer Res. 2009. PMID: 19188180 Clinical Trial.
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party.
Castagnetti F, Palandri F, Amabile M, Testoni N, Luatti S, Soverini S, Iacobucci I, Breccia M, Rege Cambrin G, Stagno F, Specchia G, Galieni P, Iuliano F, Pane F, Saglio G, Alimena G, Martinelli G, Baccarani M, Rosti G; GIMEMA CML Working Party. Castagnetti F, et al. Among authors: breccia m. Blood. 2009 Apr 9;113(15):3428-34. doi: 10.1182/blood-2007-08-103499. Epub 2009 Feb 11. Blood. 2009. PMID: 19211938 Free article. Clinical Trial.
572 results